NovoCure (NVCR) EPS (Basic) Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.15% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.72% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -1.10% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 62.43% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 10.44% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 58.74% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 26.49% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 5.98% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -7.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.43% |
| Dec 31, 2025 | 15.14% |
| Sep 30, 2025 | -9.70% |
| Jun 30, 2025 | -16.11% |
| Mar 31, 2025 | -97.89% |
| Dec 31, 2024 | -34.63% |
| Sep 30, 2024 | -29.14% |
| Jun 30, 2024 | -30.34% |
| Mar 31, 2024 | -108.01% |
| Dec 31, 2023 | -121.04% |
| Sep 30, 2023 | -92.30% |
| Jun 30, 2023 | -207.23% |
| Mar 31, 2023 | -143.85% |
| Dec 31, 2022 | -122.40% |
| Sep 30, 2022 | -143.85% |
| Jun 30, 2022 | -184.39% |
| Mar 31, 2022 | 32.49% |
| Dec 31, 2021 | -13.72% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 6.27% |
| Mar 31, 2021 | 44.18% |
| Dec 31, 2020 | 34.20% |
| Sep 30, 2020 | 39.12% |
| Jun 30, 2020 | 27.72% |
| Mar 31, 2020 | 29.87% |
| Dec 31, 2019 | 29.14% |
| Sep 30, 2019 | 27.06% |
| Jun 30, 2019 | 72.48% |
| Mar 31, 2019 | 32.36% |
| Dec 31, 2018 | 24.18% |
| Sep 30, 2018 | 60.38% |
| Jun 30, 2018 | 58.39% |
| Mar 31, 2018 | 49.35% |
| Dec 31, 2017 | 59.38% |
| Sep 30, 2017 | 55.24% |